Department of Oncological Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-808 Katowice, Poland.
Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Zabrze, Poland.
Int J Mol Sci. 2024 May 6;25(9):5045. doi: 10.3390/ijms25095045.
V-set domain-containing T-cell activation inhibitor 1 (aliases VTCN1, B7H4) participates in tumour immune escape by delivering inhibitory signals to T cells. The purpose of this article was to assess the B7H4 prognostic value in solid cancers. Three databases were searched for relevant articles. The main endpoints were overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS). Appropriate hazard ratios (HRs) were pooled. The R studio software (version 4.0.3) was used for data analysis. Thirty-one studies met the inclusion criteria. High expression of B7H4 was associated with worse OS (HR = 1.52, 95% CI: 1.37-1.68) but not with DSS (HR = 1.14, 95% CI: 0.49-2.63), RFS (HR = 1.77, 95% CI: 0.75-4.18), DFS (HR = 1.29, 95% CI: 0.8-2.09), or PFS (HR = 1.71, 95% CI: 0.91-3.2) in patients with solid cancers. High expression of B7H4 is associated with a poorer prognosis in patients with solid cancers. B7H4 is a promising prognostic biomarker and immunotherapeutic target for various solid cancers because of its activity in cancer immunity and tumourigenesis.
V -set 域包含 T 细胞激活抑制剂 1（别名 VTCN1、B7H4）通过向 T 细胞传递抑制信号参与肿瘤免疫逃逸。本文旨在评估 B7H4 在实体瘤中的预后价值。检索了三个数据库以查找相关文章。主要终点是总生存期（OS）、疾病特异性生存期（DSS）、无进展生存期（PFS）、无复发生存期（RFS）和无病生存期（DFS）。适当的风险比（HRs）进行了汇总。使用 R 工作室软件（版本 4.0.3）进行数据分析。符合纳入标准的研究有 31 项。B7H4 的高表达与较差的 OS（HR=1.52，95%CI：1.37-1.68）相关，但与 DSS（HR=1.14，95%CI：0.49-2.63）、RFS（HR=1.77，95%CI：0.75-4.18）、DFS（HR=1.29，95%CI：0.8-2.09）或 PFS（HR=1.71，95%CI：0.91-3.2）无关在患有实体瘤的患者中。B7H4 的高表达与实体瘤患者的预后较差相关。由于其在癌症免疫和肿瘤发生中的作用，B7H4 是一种很有前途的预后生物标志物和免疫治疗靶点，可用于各种实体瘤。
